Avid Bioservices
CDMO · NASDAQ
Price unavailable right now.
No price history for this range.
About CDMO
- Employees
- 371
- Headquarters
- Tustin, California
- Listed
- Oct 27, 1993
- Sector
- Health Care
- Industry
- Biotechnology
- Website
- avidbio.com
Leadership
| Name | Title | Since |
|---|---|---|
| Nicholas Green | — | 2020 |
| Daniel Hart | — | 2018 |
| Richard Richieri | — | — |
| Mark Ziebell | — | — |
| Matthew Kwietniak | — | — |
| Stephanie Diaz | — | 2020 |
Revenue by product and region
Fiscal year ended Apr 30, 2024: $139.91M total revenue
By product
- Manufacturing Revenues [Member]$119.34M85.3%
- Process Development Revenues [Member]$20.57M14.7%
Suppliers and customers
Price correlation is over one year: 1 means the stocks move together, -1 opposite
| Company | Relationship | Correlation |
|---|---|---|
| Coherus BioSciences CHRS | Customer | 0.75 |
| ADC Therapeutics ADCT | Customer | 0.65 |
| Iovance Biotherapeutics IOVA | Customer | 0.50 |
| Oragenics OGEN | Customer | 0.50 |
| Gilead Sciences GILD | Customer | 0.44 |
| IGM Biosciences IGMS | Customer | 0.44 |
| Humanigen HGEN | Supplier and customer | 0.30 |
| Halozyme Therapeutics HALO | Supplier and customer | 0.01 |
| Acumen Pharmaceuticals ABOS | Customer | — |
| Mapp Biopharmaceutical, Inc. | Customer | — |
Similar companies
Companies in the same industry as Avid Bioservices
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.